TheraRadar
← Back
Data updated: Mar 29, 2026

SAMSUNG BIOEPIS CO LTD

ImmunologyGastroenterologyOncology
Biotech

SAMSUNG BIOEPIS CO LTD is a biotechnology company focused on Immunology, Gastroenterology, Oncology.

2017
Since
11
Drugs
-
Trials
41
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

EPYSQLI 2026-01-23
REMS
ETICOVO 2025-12-05
Labeling
ONTRUZANT 2025-12-05
Labeling
EPYSQLI 2025-11-28
Efficacy
PYZCHIVA 2025-11-18
Labeling
PYZCHIVA 2025-11-18
Labeling
BYOOVIZ 2025-11-12
Labeling
EPYSQLI 2025-11-10
REMS
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Immunology 31%
3 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1
Gastroenterology 27%
4 drugs
Oncology 24%
2 drugs Phase 3: 2 Phase 1: 1
Ophthalmology 18%
1 drugs Phase 3: 2 Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Ophthalmology
AbbVie big-pharma
Immunology, Oncology, Ophthalmology
ASTELLAS specialty
Oncology, Gastroenterology, Ophthalmology, Immunology
Roche big-pharma
Oncology, Ophthalmology, Immunology